Glen Weiss to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Glen Weiss has written about Programmed Cell Death 1 Receptor.
Connection Strength
0.046
-
Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, Guo W, Lu S, Danaee H, McEachern K, Im E, Sachdev JC. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022 01; 89(1):93-103.
Score: 0.046